Test environment running 7.6.6

Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use

Loading...
Thumbnail Image

Date

Authors

Thomson, Scott
Jaramillo, Angel B
Shoobridge, Maryanne
Dunstan, Kerrie J
Everett, Beth
Ranasinghe, Charani
Kent, Stephen J
Gao, Ke
Medveczky, C
Ffrench, Rosemary A

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier

Abstract

Induction of high levels of broadly reactive cytotoxic T lymphocytes (CTL) remains a promising approach for an effective HIV-1 vaccine. We have developed a novel genetic-based vaccine strategy that encodes consensus overlapping peptide sets from all HIV-1 proteins scrambled together. This synthetic scrambled antigen vaccine (SAVINE) strategy has significant advantages, e.g. capacity to encode more antigens safely and is very flexible compared to traditional isolate-based strategies. The SAVINE vaccine strategy is clearly immunogenic, being able to restimulate a range of human HIV-1 specific responses in vitro and induce HIV-1 specific immunity in vivo in mice. Interestingly, different in vivo delivery strategies affected the resulting immunity and immunodominance pattern in mice. This platform strategy could be used for other infections and cancers where T cell responses are important for protection.

Description

Citation

Source

Vaccine

Book Title

Entity type

Access Statement

License Rights

Restricted until

2037-12-31